A regenerative graft could rethink dialysis access
NCT ID NCT06329310
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial is testing a new type of vascular graft called aXess-E for people with end-stage renal disease who need hemodialysis. The graft is made from a biodegradable polymer that is designed to be replaced by the body's own tissue over time. The study will check whether the graft is safe and works well for dialysis access in about 20 adults.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aXess-E conduit, a biodegradable polymer-based vascular graft with nitinol reinforcement for hemodialysis access
- What this could lead to
- If successful, this could provide a new, regenerative option for hemodialysis access that may reduce complications compared to traditional grafts.
- What could go wrong
- This is an early feasibility study with only 20 participants, so results may not generalize. Risks include device-related serious adverse events such as infection, thrombosis, or graft failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects with end-stage renal disease (ESRD) who require placement of an Arteriovenous Graft (AVG) in the upper extremity to start or maintain hemodialysis therapy 2. At least 18 years of age at screening 3. Suitable anatomy (e.g. a target vein with a minimum diameter of 5mm) for the implantation of an aXess-E conduit 4. The patient has been informed about the nature of the study, understands and agrees to its provisions, and has personally provided written informed consent 5. The patient has been informed and agrees to pre- and post- procedure follow-up 6. Life expectancy of at least 12 months Exclusion Criteria: 1. History or evidence of severe cardiac disease (New York Heart Association (NYHA) Functional Class IV and/or Ejection Fraction (EF) \<25%), myocardial infarction within six months of study enrolment, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina 2. Uncontrolled or poorly controlled diabetes 3. Abnormal blood values that could influence patient recovery and or/ conduit hemostasis 4. Reduced liver function, defined as: \>2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) \>1.5 or prothrombin time (PT) \>18 seconds 5. Any active local or systemic infection 6. Known heparin-induced thrombocytopenia 7. Known active bleeding disorder and/or any coagulopathy or thromboembolic disease 8. Allergies to study device (nitinol) or agents/medication, such as contrast agents or aspirin, that can't be controlled medically 9. Anticipated renal transplant within 6 months 10. Known or suspected central vein obstruction on the side of planned conduit implantation 11. Previous dialysis access conduit in the operative limb unless the aXess-E conduit can be placed more proximally than the previous failed conduit 12. Previous enrolment in this study 13. Subject is participating in another study 14. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 15. Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit Intra-operative exclusion criteria: 1\. Unsuitable anatomy to implant the aXess-E conduit (e.g. target vein and/or artery diameter smaller than anticipated; severe calcification)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
2 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Hospital de Santa Maria
RECRUITINGLisbon, Portugal
-
Kliničko bolnički centar Zvezdara Klinika za Interne Bolesti
RECRUITINGBelgrade, Serbia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a deep breath and a hint of lemongrass take the sting out of dialysis needles?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can pedaling during dialysis make red blood cells more flexible?
- 30,000 dialysis patients tracked to map what works
- Donated artery grafts tested as lifeline for dialysis patients
- Does better dialysis keep parathyroid hormone in check?